Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line

Virology

Volumn 238, Issue 2, 1997, Pages 198-211

  Carroll, Miles W ^a   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELL LINE; CELL STRAIN BHK; CHICK EMBRYO; CHO CELL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; EMBRYO; EXPRESSION VECTOR; HELA CELL; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; QUAIL; RABBIT; RHESUS MONKEY; SWINE; VACCINIA VIRUS; VIRION; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS MORPHOGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0031585552     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8845     Document Type: Article

References (43)

1. Ainsworth S. K., Karnovsky M. J. An ultrastructural staining method for enhancing the size and electron opacity of ferritin in thin sections. J. Histochem. Cytochem. 20:1972;225-229.
2. Altenburger W., Süter C.-P., Altenburger J. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch. Virol. 105:1989;15-27.
3. Antoine G., Scheiflinger F., Holzer G., Langmann T., Falkner F. G., Dorner F. Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes. Gene. 177:1996;43-46.
4. Beattie E., Kauffman E. B., Martinez H., Perkus M. E., Jacobs B. I., Paoletti E., Tartaglia J. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes. 12:1996;89-94.
5. Bender B. S., Rowe C. A., Taylor F., Wyatt L. S., Moss B., Small P. A. Oral immunization with a replication-deficient recombinant vacciinia virus protects mice against influenza. J. Virol. 70:1996;6418-6424.
6. Bertholet C., Drillien R., Wittek R. One hundred base pairs of 5′ flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc. Natl. Acad. Sci. USA. 82:1985;2096-2100.
7. Blasco R., Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000 Dalton outer envelope protein. J. Virol. 65:1991;5910-5920.
8. Carroll M. W., Moss B. E. coli β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. BioTechniques. 19:1995;352-355.
9. Carroll M. W., Overwiijk W. W., Chamberlain R. S., Rosenberg S. A., Moss B., Restifo N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model. Vaccine. 15:1997;387-394.
10. Chang H.-W., Uribe L. H., Jacobs B. L. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69:1995;6605-6608.
11. Chang H. W., Watson J. C., Jacobs B. L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 89:1992;4825-4829.
12. Dallo S., Rodriguez J. F., Esteban M. A 14K envelope protein of vaccinia virus with an important role in virus-host cell interactions is altered during virus persistence and determines the plaque size phenotype of the virus. Virology. 159:1987;423-432.
13. Drillien R. D., Spehner D., Kirn A. Host range restriction of vaccinia virus in Chinese hamster ovary cells: Relationship to shutoff of protein synthesis. J. Virol. 28:1978;843-850.
14. Duncan S. A., Smith G. L. Identification and characterization of an extracellular envelope glycoprotein affecting vaccinia virus egress. J. Virol. 66:1992;1610-1621.
15. Earl P. L., Cooper N., Moss B. Preparation of cell cultures and vaccinia virus stocks. Current Protocols in Molecular Biology. 1991;GreeneWiley Interscience, New York. p. 16.16.1-16.16.7.
16. Earl P. L., Moss B. Generation of recombinant vaccinia viruses. Ausubel F. M., Brent R., Kingston R. E., Moore D. D., Seidman J. G., Smith J. A., Struhl K. Current Protocols in Molecular Biology. 1991;16.17.1-16.17.16 GreeneWiley Interscience, New York.
17. Engelstad M., Smith G. L. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology. 194:1993;627-637.
18. Gillard S., Spehner D., Drillien R. Mapping of a vaccinia virus host range sequence by insertion into the viral thymidine kinase gene. J. Virol. 53:1985;316-318.
19. Hirsch V. M., Fuerst T. R., Sutter G., Carroll M. W., Yang L. C., Goldstein S., Piatak M. Jr., Elkins W. R., Alvord W. G., Montefiori D. C., Moss B., Lifson J. D. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
20. Hochstein-Mintzel V., Huber H. C., Stickl H. Virulenz und immunogenität eines modifizierten vaccinia-virus (Stamm MVA). Z. Immun. Forsch. 144:1972;140-145.
21. Katz S. L., Broome C. V. Vaccinia (smallpox) vaccine. Recommendations of the immunization practices advisory committee (ACIP). Morbid. Mortal. Week. Rep. 40:1991;1-10.
22. Mahnel H., Mayr A. Erfahrungen bei der schutzimpfung gegen orthopocken von mensch und tier mit dem impfstamm MVA. Berl. Münch. Tierärzt. Wschr. 107:1994;253-256.
23. Martinez-Pomares L., Stern R. J., Moyer R. W. The ps/hr gene (B5R open reading frame homolog) of rabbitpox virus controls pock color, is a component of the extracellular enveloped virus, and is secreted into the medium. J. Virol. 67:1993;5450-5462.
24. Mayr A., Hochstein-Mintzel V., Stickl H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA. Infection. 3:1975;6-14.
25. Mayr A., Stickl H., Müller H. K., Danner K., Singer H. Der pockenimpfstamm MVA: Marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwächten organismus. Zbl. Bakt. Hyg. 167:1978;375-390.
26. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1991;1031-1038.
27. Moss B., Rosenblum E. N., Katz E., Grimley P. M. Rifampicin: A specific inhibitor of vaccinia virus assembly. Nature. 224:1969;1280-1284.
28. Njayou M., Drillien R., Kirn A. Characteristics of the inhibition of protein synthesis by vaccinia virus in nonpermissive Chinese hamster ovary cells. Ann. Virol. 133:1982;393-402.
29. Oguiura N., Spehner D., Drillien R. Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J. Gen. Virol. 74:1993;1409-1413.
30. Perkus M. E., Goebel S. J., Davis S. W., Johnson G. P., Limbach K., Norton E. K., Paoletti E. Vaccinia virus host range genes. Virology. 179:1990;276-286.
31. Ramsey-Ewing A., Moss B. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis. Virology. 206:1995;984-993.
32. Ramsey-Ewing A. L., Moss B. Complementation of a vaccinia virus host range K1L gene deletion by the non-homologous CP77 gene. Virology. 222:1996;75-86.
33. Rodriguez J. F., Smith G. L. IPTG-dependent vaccinia virus: Identification of a virus protein enabling virion envelopment by Golgi membrane and egress. Nucleic Acids Res. 18:1990;5347-5351.
34. Scheiflinger F., Falkner F. G., Dorner F. Evaluation of the thymidine kinase (tk. Arch. Virol. 141:1996;663-669.
35. Stickl H., Hochstein-Mintzel V., Mayr A., Huber H. C., Schäfer H., Holzner A. MVA-stufenimpfung gegen pocken. Kleinische erprobung des attenuierten pocken-lebendimpfstoffes, stamm MVA. Dtsch. Med. Wschr. 99:1974;2386-2392.
36. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA. 89:1992;10847-10851.
37. Sutter G., Ohlmann M., Erfle V. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 371:1995;9-12.
38. Sutter G., Wyatt L. S., Foley P. L., Bennink J. R., Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
39. Wolffe E. J., Isaacs S. N., Moss B. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67:1993;4732-4741.
40. Wolffe E. J., Katz E., Weisberg A., Moss B. The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J. Virol. 71:1997;3904-3915.
41. Wolffe E. J., Moore D. M., Peters P. J., Moss B. Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J. Virol. 70:1996;2797-2808.
42. Wyatt L. S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 210:1995;202-205.
43. Wyatt L. S., Shors S. T., Murphy B. R., Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 14:1996;1451-1458.